EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data

Sarah A Buckley, Suliman Al-Fayoumi, James P Dean, Jessica Zhang, Purvi Suthar, Muriel Richard

Clinical Pharmacology in Drug Development · 2026-06 · 15 (6)

DOI: 10.1002/cpdd.70070 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 29.05.2026. Verfasst von Sarah A Buckley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sobi, Inc., Waltham, MA, USA. Hauptthemen laut MEDLINE: Pyrimidines, Long QT Syndrome, Primary Myelofibrosis, Protein Kinase Inhibitors. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sobi, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pacritinib, an inhibitor of JAK2/IRAK1/ACVR1 that is devoid of JAK1 activity, approved for treating myelofibrosis in patients with severe thrombocytopenia, carries a label warning for QT interval prolongation. To evaluate the cardiac safety of pacritinib, a randomized, placebo‐ and active‐controlled, single‐dose thorough QT (TQT) study was conducted in healthy subjects, and a dose‐finding study (PAC203) was conducted in patients with myelofibrosis. In the TQT study, 42 subjects received single doses of pacritinib 400 mg, moxifloxacin 400 mg (positive control), and placebo in a crossover design. The maximal placebo‐corrected change in QT interval with pacritinib was −9.7 ms (90% confidence interval: −13.4, −6.1), and all upper confidence bounds were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesLong QT SyndromePrimary MyelofibrosisProtein Kinase InhibitorsHeart RateHumansFemaleCross-Over StudiesMaleElectrocardiographyDose-Response Relationship, DrugAdultMiddle AgedProspective StudiesDouble-Blind MethodAgedYoung AdultMoxifloxacinBridged-Ring Compounds

Stichwörter der Autor:innen

QT intervalcardiac safetymyelofibrosispacritinibpharmacokinetics

Substanzen

PyrimidinespacritinibProtein Kinase InhibitorsMoxifloxacinBridged-Ring Compounds

Autor:innen und Institutionen

  • Sobi, Inc., Waltham, MA, USA.
  • Sobi, Inc. (successor in interest to CTI BioPharma Corp), Seattle, WA, USA.
  • Sobi, Basel, Switzerland.

Förderung

  • Sobi, Inc.

Zitieren

APA

Buckley, S. A., Al-Fayoumi, S., Dean, J. P., Zhang, J., Suthar, P., & Richard, M. (2026). Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data. Clinical Pharmacology in Drug Development, 15(6). https://doi.org/10.1002/cpdd.70070

Vancouver

Buckley SA, Al-Fayoumi S, Dean JP, Zhang J, Suthar P, Richard M. Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data. Clinical Pharmacology in Drug Development. 2026;15(6). doi:10.1002/cpdd.70070

BibTeX
@article{Buckley2026,
  author = {Buckley, Sarah A and Al-Fayoumi, Suliman and Dean, James P and Zhang, Jessica and Suthar, Purvi and Richard, Muriel},
  title = {Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cpdd.70070}
}
Kostenlos starten →